By Mike CherneySYDNEY--Australia-based pharmaceuticals company CSL said half-year statutory net profit rose by 17%, reflecting a strong performance in its main blood-plasma business. CSL said its statutory net profit in the six months through December was US$1.90 billion. Total statutory revenue rose 12% to US$8.05 billion, compared to market expectations of US$7.94 billion, according to FactSet. When foreign-exchange movements were stripped out, CSL said its net profit rose by 20% to US$1.94 billion. Underlying profit rose by 13% to US$2.06 billion at constant exchange rates, while annual revenue rose by 11% to US$7.95 billion, CSL said.

Source: Wall Street Journal February 12, 2024 21:50 UTC